The role of renal transporters and novel regulatory interactions in the TAL that control blood pressure by Graham, Lesley A. et al.
 
 
 
 
 
Graham, L. A., Dominiczak, A.  and Ferreri, N. R. (2017) The role of renal 
transporters and novel regulatory interactions in the TAL that control blood 
pressure. Physiological Genomics, 49(5), pp. 261-276. 
(doi:10.1152/physiolgenomics.00017.2017)  
 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
http://eprints.gla.ac.uk/139978/ 
     
 
 
 
 
 
 
Deposited on: 27 April 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk33640 
1 
 
Authors: Lesley A. Graham1, and Anna F. Dominiczak1, Nicholas R. Ferreri2.  1 
Title: The role of renal transporters and novel regulatory interactions in the TAL that control blood pressure. 2 
Abstract: Hypertension (HTN), a major public health issue is currently the leading factor in the global burden of 3 
disease, where associated complications account for 9.4 million deaths worldwide every year (98). Excessive 4 
dietary salt intake is among the environmental factors that contribute to HTN, known as salt sensitivity. The 5 
heterogeneity of salt sensitivity and the multiple mechanisms that link high salt intake to increases in blood 6 
pressure are of upmost importance for therapeutic application. A continual increase in the kidney’s reabsorption 7 
of sodium (Na+) relies on sequential actions at various segments along the nephron. When the distal segments of 8 
the nephron fail to regulate Na+, the effects on Na+ homeostasis are unfavourable. We propose that the specific 9 
nephron region where increased active uptake occurs as a result of variations in Na+ reabsorption is at the thick 10 
ascending limb of the loop of Henle (TAL). The purpose of this review is to urge the consideration of the TAL 11 
that contributes to the pathophysiology of salt sensitive HTN. Further research in this area will enable 12 
development of a therapeutic application for targeted treatment. 13 
Keywords: Thick ascending limb of the loop of Henle, hypertension, salt sensitivity, sodium, kidney. 14 
Introduction 15 
Essential hypertension (HTN) is a highly hereditable trait of complex aetiology, where multiple genetic and 16 
environmental factors contribute to blood pressure variation. The study of genetic architecture has proven useful 17 
to detect a small number of genes, loci, and single nucleotide polymorphisms (SNPs) that have appreciable 18 
effects on blood pressure (40, 94, 123). Among the environmental factors that contribute to HTN, excessive 19 
dietary salt intake is one of the common and important risk factor (31). The link between dietary salt intake and 20 
HTN is well established and a reduction in salt intake is known to lower blood pressure (BP) (29, 137). Albeit, 21 
individuals respond differently to dietary salt; the increase in BP with an increase in salt intake occurs in some 22 
individuals, whereas others show no significant change in BP (179). This phenomenon is known as salt 23 
sensitivity, which is estimated to be present in 51% of the hypertensive and 26% of the normotensive 24 
populations (67, 68). Although salt sensitivity is a well-established phenomenon in experimental and human 25 
hypertension, the pathophysiological mechanisms are not fully elucidated (7). The heterogeneity of salt 26 
sensitivity and the multiple mechanisms that link high salt intake to increases in BP are important for clinical 27 
application. To this end many studies over the decades have focused on elucidating the pathophysiological 28 
mechanisms of salt sensitivity and the associated risk of developing HTN using; epidemiological studies (70, 29 
148), clinical trials (1, 2, 53, 106, 180, 181), in vivo studies (11, 33, 36), and more recently systems approaches 30 
by means of metabolomics (110, 167); proteomics (58, 115); and transcriptomics (reviewed in (39, 125)). Even 31 
so, historical research on salt handling and blood pressure control has been vigorously perused demonstrating 32 
long term regulation of BP relies on the synchronised regulation of  Na+ (sodium), K+ (potassium), and Cl- 33 
(chloride) movement in the kidney to maintain blood volume and water balance (60, 70) (97). 34 
The ability of the kidneys to absorb large quantities of Na+ relies on sequential actions at various segments 35 
along the nephron, each with highly specialised transport capacities (outlined in Figure 1). Na+ transport along 36 
the nephron is flow dependant, and a basic form of communication between parts of the nephron occurs as a 37 
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result of changes in Na+ delivery by altered glomerular filtration rate (GFR). These alterations effect Na+ 38 
reabsorption in the upstream segments of the nephron, provoking and a change in delivery/absorption of Na+ to 39 
the downstream nephron (133). Suggesting the regulation of Na+ reabsorption is highly controlled at the distal 40 
nephron, and failure of these downstream segments have more adverse effects on Na+ homeostasis that 41 
alterations that occur in the proximal tubule. Proposing, that sustained increases of Na+ reabsorption at the distal 42 
segments of the nephron is generated by a higher natriuretic pressure, and the specific nephron region where 43 
increased active uptake occurs as a result of variations in Na+ reabsorption is at the thick ascending limb of the 44 
loop of Henle (TAL). Accordingly, this review will discuss the evidence implicating variations of Na+ 45 
reabsorption at the TAL which are detrimental to sodium homeostasis and blood pressure control. This review 46 
will direct future studies to consider the TAL when investigating the pathophysiological mechanisms of salt 47 
sensitivity and HTN which will aid the search for precise therapies for essential hypertension. 48 
ION TRANSPORT ALONG THE THICK ASCENDING LIMB OF THE LOOP OF HENLE 49 
Anatomy and morphology of the loop of Henle 50 
The loop of Henle encompasses the thin descending limb, the thin ascending limb, and the TAL (Figure 2). 51 
Within the inner stripe of the outer medulla there are short looped nephrons that derive from superficial and 52 
mid-cortical nephrons. These segments have a short descending limb and close to the hairpin turn of the loop, 53 
these tubules merge into the TAL. In contrast, the long-looped nephrons (originating from juxtamedullary 54 
glomeruli) have a long ascending thin limb where the TAL begins at the boundary between the inner and outer 55 
medulla. The TAL proceeds immediately after the thin ascending limb of long-looped nephrons. Aquaporin 1 56 
(AQP1) is expressed abundantly in the proximal tubule; however, expression of AQP1 is also used as a marker 57 
to determine the junction between thin limbs of the loops of Henle and the TAL (124). The TAL begins after an 58 
AQP1 negative segment of short-limbed nephrons, immediately following the AQP1 positive thin descending 59 
limb (119, 124). Near the end of the TAL, the nephron passes between its afferent and efferent arterioles and 60 
meets its parent glomerulus; the macula densa (MD) constitutes the tightly packed epithelial cells at the junction 61 
of the TAL and the distal convoluted tubule (DCT) (119).  62 
Characteristics of the thin descending limb include: high water permeability and low permeability for Na+ and 63 
urea, with exceedingly low expression of Na+-K+-ATPase. Therefore, this segment is unlikely to contribute 64 
markedly to renal Na+ reabsorption. Thin ascending limbs reabsorb some Na+, but this absorption is likely 65 
passive as Na+-K+-ATPase expression is low (150). The TAL is the major Na+ reabsorbing segment of the 66 
nephron accounting for approximately 20%–25% of filtered sodium chloride (NaCl). Features of the TAL 67 
include: maintenance of the extracellular fluid (ECF), regulation of arterial haemodynamics, and regulation of 68 
NaCl homeostasis contributing to the regulation of the urinary concentrating mechanisms. It is essential for the 69 
kidney to osmotically concentrate the urine above isotonicity; this is dependent on Na+ reabsorption in the 70 
absence of measurable water permeability (124). Specifically, active NaCl absorption by the TAL dilutes 71 
luminal fluid to drives the counter current gradient that generates the axial osmolality gradient in the outer 72 
medulla region (119). The MD cells sense luminal NaCl concentrations and share most transport properties with 73 
TAL cells even though they are distinct in aspects of tubuloglomerular feedback (TGF). An increase of luminal 74 
NaCl at the MD generates a signalling cascade that induces vasoconstriction of the afferent arterioles which 75 
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reduces GFR. The augmented uptake of NaCl at the MD via the Na+-K+-Cl- transporter (NKCC2) mediates TGF 76 
(71, 133). These signals cause the release of ATP into the juxtaglomerular interstitium and the subsequent 77 
generation of the nucleoside adenosine that constricts afferent arterioles (93). Figure 3 outlines the main ion 78 
transporters found at each nephron segment.  79 
Thick ascending limb – Principal ion transporters. 80 
At least 80% of NaCl uptake across the apical membrane of TAL cells is mediated by a co-transport process in 81 
which the influx of Na+ drives the uptake of Cl- and K+. To achieve net salt absorption, apical electroneutral co-82 
transport of Na+, K+, and Cl- via NKCC2 is complemented by recycling of K+ via ROMK, efflux of Cl- via 83 
basolateral Cl- channels (CLC- Kb/Barttin), coupled transport of Na+ and H+ via NHE3 transporters, basolateral 84 
extrusion of Na+ by Na+ -K+ -ATPase, and the final adjustment to urine concentration, K+ homeostasis, acid base 85 
balance with Na+ reabsorption is accomplished by ENaC (8).  86 
The Na+ /H+ exchangers (NHEs) are typical Na+ coupled transporters that mediate the counter transport of one 87 
extracellular Na+ for one cytosolic proton (H+) at the luminal apical membrane in the TAL. NHE3 is confined 88 
mainly to the apical membrane of renal cells (6), and functions by direct reabsorption of filtered Na+ along with 89 
indirect reabsorption of bicarbonate (HCO3-) and chloride and secretion of ammonium. The NHE3 anti-porters 90 
are positioned at the luminal apical membrane in the proximal convoluted tubule and the TAL and are 91 
responsible for reabsorbing up to 70% of filtered Na+. NHE3 transports Na+ into the cell in exchange for H+ into 92 
the tubular lumen by the electrochemical gradient produced by Na+-K+-ATPase. The secreted H+ combines with 93 
HCO3- to form H2O and CO2 and the latter diffuses into cells. Carbonic anhydrase (CA) allows rapid conversion 94 
of H2CO3 into H2O and CO2. Secreted H+ generates OH- inside the cell which is then converted into HCO3- by 95 
combining with CO2. The HCO3- leaves the cell via the basolateral Na+ -3HCO3- co-transporter (adapted from 96 
(149)) (Figure 4A).     97 
NKCC2 is localised at the apical membrane of the TAL. The function of this co-transporter is to reabsorb Na+ 98 
without reabsorbing water. Na+, K+, and Cl- are transported into the cell across the apical membrane at a 99 
stoichiometry of 1:1:2 via the electrochemical gradient of the sodium pump. Na+ and Cl- are transported into the 100 
peritubular fluid while K+ re-cycles back into the tubular lumen via ROMK (8). NKCC2 mediates approximately 101 
90-100 % of Cl- reabsorption, and 30- 50 % of all Na+ transport, furthermore its function is linked with 102 
paracellular Na+, Ca+, and Mg+ flux (73).  For each Na+ ion transported into the cell by NKCC2, 1 Na+ ion is 103 
absorbed via paracellular pathways. Inhibition of NKCC2 results in decreased K+ exit through ROMK halting 104 
NaCl reabsorption and paracellular transport of Ca+ and Mg+ (72, 76). ROMK channels supply a sufficient 105 
amount of K+ to the NKCC2 co-transporter to maintain reabsorptive transport of NaCl. As Na+ transport of 106 
NKCC2 is rate limited by the availability of luminal K+ in the TAL, changes in activity of ROMK has 107 
regulatory effects of NaCl reabsorption (46) (Figure 4B). Previous immunolocalisation experiments revealed 108 
that NKCC2 is expressed at the apical cell surface of the TAL and MD but also in subapical vesicles, where 109 
intracellular trafficking regulates NKCC2 membrane expression. Vasopressin has been shown to shuttle the 110 
subapical vesicles of NKCC2 to the apical surface, leading to enhanced activity and expression levels (54). The 111 
transporter undergoes constitutive exocytosis at the TAL (27) suggesting NKCC2 trafficking is a dynamic 112 
continuous event rather than a triggered action. It was reported by Ares et al that endocytosis and recycling of 113 
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NKCC2 in the absence of stimuli results in the retrieval of the protein from the plasma membrane at a rate  that 114 
is closely matched to that of exocytosis insertion (8). These reports suggest that under basal conditions and in 115 
the absence of stimuli dynamic trafficking of NKCC2 occurs. Three NKCC2 isoforms (A, B, and F) are derived 116 
by differential splicing of exon 4 of the SLC12A1 gene. These isoforms differ in their distribution along the 117 
nephron and account for 20%, 10% and 70%, for A, B, and F respectively, of the total NKCC2 transcript 118 
abundance in mice (28). NKCC2A is located in the medullary and cortical TAL and exhibits immediate affinity 119 
for Cl-, whereas NKCC2B shows highest affinity for Cl- and is primarily located in the macula densa cells and 120 
cortical region. NKCC2F has the lowest affinity for ion transport, however, is mainly located in the medullary 121 
TAL. The relative distribution of these isoforms and affinity for ion transport matches the luminal concentration 122 
of NaCl along the TAL. Mice lacking NKCC2A revealed lower urine osmolality and decreased Cl- reabsorption 123 
with enhanced expression of NKCC2B indicating compensation (135).  124 
The basolateral Na+/K+-ATPase is the primary exit pathway for Na+ at the basolateral membrane of TAL cells. 125 
This transporter is composed of α, β, and γ subunits where studies have demonstrated the α subunit at the TAL 126 
participates in the natriuretic response to salt load (101). Suppression of Na+ K+/ATPase activity markedly 127 
increases intracellular sodium (127). Studies have shown that rodents fed high salt diets display reduced levels 128 
of Na+ K+/ATPase in the renal tissues (105) and pigs administered deoxycorticosterone plus 1% NaCl in the 129 
drinking water develop reduced natriuresis increasing Na+ K+/ATPase inactivity by 30 fold and resulting in 130 
augmented arterial pressure (63). The activity of Na+/K+-ATPase generates a Na+ gradient that enables apical 131 
entry of Na+, K+, and Cl− via NKCC2. Ouabain can inhibit the activity of Na+/K+-ATPase, leading to the 132 
collapse of the lumen positive potential. This in turn abolishes the transepithelial Na+-Cl- transport at the TAL 133 
(75). Cl− channels primarily mediate basolateral exit of Cl− from TAL cells, there are two chloride channels co-134 
expressed at the TAL; CLC-K1 and CLC-K2 (denoted CLC-NKA and CLC-NKB in humans), with the 135 
dominant Cl− channel in the TAL being encoded by CLC-NKB (178). The characterisation of “Barttin” which is 136 
co-expressed with CLC-K2 in several nephron segments, including the TAL has aided the physiological 137 
understanding of the TAL. The human CLC-NKA and CLC-NKB paralogs do not function correctly in the 138 
absence of Barttin co-expression. CLC-NKB co-expressed with Barttin is highly selective for Cl− (44).   139 
Paracellular transport 140 
Crossing the tubular epithelium can be performed in a single step (paracellular) or a twostep processes 141 
(transcellular). The paracellular route of ionic flow occurs when the substance goes through the matrix of the 142 
tight junctions that link each epithelial cell to its neighbouring cell, an example of paracellular movement is the 143 
reabsorption of calcium and magnesium. The TAL reabsorbs approximately 50%–60% of filtered magnesium 144 
and approximately 20% of filtered calcium, exclusively via the paracellular pathway (119). A lumen-positive 145 
transepithelial voltage (Vte) drives the paracellular reabsorption of Mg2+ and Ca2+. The generation of Vte can be 146 
caused by the active transport due to apical K+ secretion through ROMK and basolateral Cl− exit through ClC-147 
Kb/barttin channels (78). Therefore, the paracellular channels function by being charge and size selective. In 148 
particular, the charge and size selectivity of the tight junctions of the epithelia is predominantly by the claudins, 149 
a large gene family of tetraspan transmembrane proteins. Claudins are the key components of the paracellular 150 
pathway. Defects in claudin 16 and 19 result in a range of renal diseases, including hypomagnesemia, 151 
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hypercalciuria and nephrolithiasis. The claudin 16 channel provides cation permeability to the tight junction and 152 
the claudin 19 channel increases the cation selectivity of the tight junction alongside the diffusional Vte by 153 
selectively blocking anion permeation. Additionally, claudin 19 interacts with claudin 16 to increase the overall 154 
cation selectivity of the tight junction. Removal of either of these claudins results in the tight junctions loosing 155 
cation selectivity, creating renal defects in Mg2+ and Ca2+ reabsorption (78). Genetic studies in human suffering 156 
hereditary hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), have demonstrated that 157 
claudin 16 and claudin 19 play an associated role in the cation selectivity of TAL tight junctions. In vivo the 158 
knockdown of claudin 16 increases Na+ absorption in the collecting duct, accompanied by increases of ECF 159 
volume after treatment with amiloride (77, 79). Mice lacking Claudin-19 exhibit increased natriuresis with 160 
marked elevations in serum aldosterone, both strains replicating the phenotypes of human FHHNC (79). 161 
Collectively, these studies illustrate the vital role of claudin-16 and claudin-19 at the tight junctions of the TAL, 162 
representing contributing significantly to the selectivity of transepithelial absorption of Na+, Ca2+, and Mg2+.  163 
REGULATION OF ION TRANSPORT AT THE THICK ASCENDING LIMB BY ALTERED 164 
LUMINAL FLOW   165 
Tubular luminal flow in the nephron constantly changes, where the rate of luminal flow varies acutely in 166 
response to changes of e.g. glomerular hemodynamics and/or changes in upstream fluid reabsorption. Increases 167 
in luminal flow are associated with enhanced Na+ reabsorption at major sites along the nephron (24-26, 128) and 168 
chronic increases in luminal flow are observed in HTN. Thus it is important to understand the cellular 169 
mechanisms in which each nephron segment senses and responds to changes in flow by appropriately altering 170 
transport rates. In vivo microperfusion studies have provided much of the evidence for flow dependent NaCl 171 
reabsorption along the TAL. The mechanisms of signalling events and interactions between soluble mediators 172 
and mechanical forces at the TAL have yet to be defined. Nevertheless, the actions of furosemide on NaCl 173 
reabsorption enforces that flow dependence of loop Na+ transport is mediated mainly by the TAL (153, 185). 174 
Wright and colleagues report a 4-fold increase in flow rate leads to a doubling of NaCl reabsorption, 175 
demonstrating that fractional reabsorption of NaCl falls with increasing flow rates (185). Flow dependence of 176 
TAL NaCl transport relies on the activity of NKCC2 (57). At times of low luminal flow, NaCl concentrations 177 
decrease along the TAL. If flow rate elevates, the drop in NaCl concentration is reduced, leading to higher 178 
luminal concentrations of NaCl that augment NaCl transport. In these conditions, minimum NaCl concentrations 179 
are not reached, resulting in flow-dependent increases in NaCl concentration at the TAL (133). The regulation 180 
of function along the TAL and NaCl transport capacities at this nephron segment are regulated by numerous 181 
biological factors, such as; autacoids, hormones, and eicosanoids. Increased intracellular cAMP stimulates 182 
transepithelial NaCl transport in the TAL, specifically; vasopressin (AVP), parathyroid hormone (PTH), 183 
glucagon, calcitonin, and β-adrenergic receptor signalling (49). This activation can subsequently be modulated 184 
by a number of negative influences, notably prostaglandin E2 (PGE2), extracellular Ca2+, hormones and 185 
autocoids working via cGMP-dependent signalling, including nitric oxide, all having powerful negative effects 186 
on NaCl transport within the TAL (8).  187 
Mechanisms that activate NKCC2 188 
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The most extensively studied activating modulator of NaCl transport in the TAL is vasopressin (AVP), mediated 189 
via the V2 receptor (122). Vasopressin activates NKCC2 in perfused mouse TAL segments exerting longer-term 190 
effects on NKCC2 expression and function at the apical surface. Previous immunohistochemical localisation 191 
experiments revealed that NKCC2 is expressed not only at the apical cell surface but also in subapical vesicles, 192 
where intracellular trafficking regulates NKCC2 membrane expression. Vasopressin has been shown to facilitate 193 
the shuttling of NKCC2 in subapical vesicles to the apical membrane, leading to enhanced activity and 194 
expression levels (54). In vivo studies have demonstrated that the phosphorylation of NKCC2 is associated with 195 
a cluster of N-terminal threonines residues (54). Rats treated with desmopressin showed induced 196 
phosphorylation of these residues, which are substrates for the homologous STE20/SPS1-related 197 
proline/alanine-rich kinase (SPAK) and oxidative stress–responsive kinase 1 (OSR1) kinases (54). These 198 
kinases mediate hypotonicity and low chloride induced activation of NKCC2 and sodium reabsorption. Studies 199 
have shown that NKCC2 phosphorylation is mainly driven by OSR1 abundance whereas SPAK abundance is 200 
responsible for NCC phosphorylation (99, 116, 190). SPAK and OSR1, are activated by upstream WNK (with 201 
no lysine [K]) kinases and the N terminus of NKCC2 contains binding sites for SPAK and OSR1 (35) (51), 202 
where OSR1 kinase has been reported as responsible for N-terminal phosphorylation of NKCC2 and is critical 203 
for activity of the transporter. Reduced N-terminal NKCC2 phosphoprotein in mice with targeted TAL-specific 204 
deletion of OSR1 results in the loss of function of the TAL. Lin et al generated global and tubule specific ORS1 205 
knockout mice, and found global knockout was embryonically lethal whereas tubule specific OSR1+/- mice 206 
displayed lower BP associated and reduced phosphorylated NKCC2 and NCC (99). The tubule specific 207 
knockout mice had reduced Na+ reabsorption at the TAL and a blunted response to furosemide with 208 
significantly reduced pNKCC2. They also demonstrated that total expression of SPAK and pSPAK was 209 
increased in parallel to NCC despite unchanged NKCC2 expression. Suggesting that, ORS1 is necessary for BP 210 
and renal sodium reabsorption via activation of NKCC2. The only upstream stimulators of SPAK/OSR1 are the 211 
family of with-no-lysine kinases (WNKs); WNK1, WNK2, WNK3, and WNK4. Phenotypic studies of WNK 212 
“knock-in” mice have demonstrated the role of the upstream WNK kinases in which mutant SPAK or OSR1 213 
cannot be activated by upstream WNK kinases; these mice have reduced phosphorylation of NKCC2 and NCC, 214 
with associated salt-sensitive hypotension (119, 141). These studies report that WNK kinases appear to regulate 215 
SPAK/OSR1 and NKCC2 in chloride-dependent fashion, phosphorylating and activating SPAK/OSR1 and the 216 
transporter in response to changes in intracellular Cl− activity as a result of altered luminal flow and NaCl 217 
uptake at the TAL (136).  The effect of hypotonicity/low Cl- on NKCC2 is enhanced/activated by WNK3 i.e. a 218 
decreased intracellular Cl- induces phosphorylation of NKCC2 to enhance its activity. The loss of WNK3 219 
expression is compensated by WNK1 (117). One group used wild type (WT) and WNK3-/- mice and studied 220 
GFR, renin levels, urine output, urine osmolarity during a normal diet and a salt restricted diet. WNK1 was 221 
markedly increased in WNK3-/- mice compared with WT during a normal diet. During a salt restricted diet, 222 
levels of pSPAK/OSR1, pNKCC2, and pNCC were upregulated in WNK3-/- mice. These mice also displayed 223 
increased diuresis in response to hydrochlorothiazide. Therefore, WNK3 may function as a Cl- sensor in TAL 224 
cells (130).  225 
WNKs are thought to regulate renal outer medulla ROMK by interacting with intersectin and influencing 226 
clathrin mediated endocytosis. He et al have demonstrated that ROMK is inhibited by WNK1 and WNK4 due to 227 
increased endocytosis of the channel (69). WNK4 phosphorylates tight junction proteins claudins 1-4 to regulate 228 
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the paracellular chloride permeability (86, 187). This paracellular chloride permeability in cells expressing 229 
mutant WNK4 is much greater than that of cells expressing WT WNK4 proteins. Demonstrating that HTN in 230 
patients with WNK4 mutations is caused by increased NaCl reabsorption (18, 87, 188). The endocytosis occurs 231 
via clathrin coated vesicles, amongst these, intersectin which contains Src-homology 3 domains that can intercat 232 
with PXXP proline rich motifs (88).  The interaction between WNK1 and WNK4 was specific to intersectin via 233 
the WNK proline rich motifs but not their kinase activity. When intersectin was knocked out the endocytosis of 234 
ROMK was prevented, providing a molecular mechanism for stimulation of ROMK endocytosis and reduced 235 
expression by WNK kinases.  236 
 237 
Tumour necrosis factor (TNF) as a negative regulator of the TAL 238 
TNF is produced by and affects the functions of several renal cell types including proximal tubule (PT), TAL, 239 
and collecting duct (CD) as well as podocytes and mesangial cells (34, 52, 83, 91, 107, 109, 113, 147). While 240 
TNF is best known for its pro-inflammatory actions, this cytokine also exhibits immunosuppressive, 241 
immunomodulatory, and regulatory effects in diverse tissues including kidney, lung, and colon, where active 242 
Na+ transport is important for fluid clearance and other transport mechanisms (5, 21, 30, 42, 43, 114, 146). Data 243 
from TNF knockout mice and the clinical use of anti-TNF drugs have exposed intrinsic effects of this cytokine 244 
that preclude the neutralization of TNF in heart failure and SLE, for example (42, 82, 89, 112, 134, 169, 184, 245 
193). Context-dependent effects of TNF also are observed in blood pressure regulation where studies have 246 
documented the pro-hypertensive effects of TNF in experimental models involving inflammation, however, 247 
TNF does not increase blood pressure in all models of hypertension and does not elevate blood pressure per se 248 
when given to normal animals (4, 41, 45, 61, 92, 111, 120, 144, 164, 173, 175). Collectively, these studies infer 249 
the importance of determining the mechanisms that subserve both the beneficial and deleterious effects of TNF 250 
in individual cell types as an approach that may facilitate the development of cell-targeted therapies.   251 
Moreover, it is important to determine if the autocrine inhibitory effects of TNF on TAL cells involving NKCC2 252 
in vitro, which are consistent with the TNF-dependent polyuria and natriuresis observed in various studies, are 253 
operational in vivo (14, 43, 45, 64, 154, 155, 171). Defining the role of TNF in vivo for individual cell types is 254 
noteworthy since there are conflicting accounts, for instance, of TNF effects on amiloride-sensitive Na+ 255 
transport, where it inhibits transport in vivo (108) while stimulating it in vitro (176). Similarly, the sensitizing 256 
effect of TNF to increase ENaC activity in distal tubules from diabetic rats contrasts with its effects in control 257 
rats or mice where TNF inhibits ENaC activity (12, 38, 108). The heterogeneity of tubular epithelial cells may 258 
necessitate distinct regulatory mechanisms for each cell type by molecules such as TNF that affect the 259 
expression and activity of assorted transporters including NHE8, SGLT2, NKCC2, ENaC, and Na+-K+-ATPase 260 
(12, 14, 38, 109, 176, 186). Renal transporters must be tightly regulated and coordinated to maintain Na+ and 261 
blood pressure homeostasis and new models are being generated to help advance the field by uncovering the in 262 
vivo effects of TNF derived from an individual nephron segment, the TAL, where variations in Na+ 263 
reabsorption have been linked to hypertension (47, 85). Understanding how autocrine cascades in the TAL 264 
operate in normal and diseased states may provide insight towards the development of new ‘loop diuretic’ 265 
therapies that could offer fine-tuning of Na+ reabsorption via discrete targeting of regulatory molecules.   266 
UROMODULIN 267 
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Protein structure 268 
Uromodulin (UMOD) is a kidney protein exclusively synthesised at the TAL and is encoded by the UMOD 269 
gene. Based on the cDNA sequence, the UMOD precursor is composed of 640 amino acid residues and motifs 270 
include signal sequence residues 1 – 24, 1 epidermal growth factor like and 2 calcium binding epidermal growth 271 
factor like domains (residues 31 – 64, 65 – 107, and 108 – 149), 1 zona pellucid domain at residues 334 - 585 272 
(this is essential for polymerisation), 8 potential N-glycosylation sites, and 1 stretch of hydrophobic amino acids 273 
similar that acquire glycosylphosphatidylinositol (GPI) attachment site (residue 614). There are 48 cysteine 274 
residues involved in disulphide bond formation (62). It was proposed an additional epidermal growth factor like 275 
domain spanning residues 281 – 336 was present in the region between the 2nd calcium binding epidermal 276 
growth factor domain and zona pellucida domain. However, a new domain D8C (residues 199-287), common to 277 
families of proteins including liver specific zona pellucida, glycoprotein 2, UMOD and several other 278 
uncharacterised proteins was described by Yang et al (189).  279 
UMOD is GPI anchored to the apical plasma membrane, thus its biosynthesis and intracellular trafficking 280 
proceed through a secretory pathway. During biosynthesis, the UMOD precursor is translocated to the ER 281 
(endoplasmic reticulum). The signal peptide is then cleaved and the protein glycosylated on 7 of the 8 potential 282 
N-glycosylation sites. Disulphide bridges are formed and glypiation on its C terminus occurs, the Golgi 283 
apparatus further modifies the N-glycan moieties. The mature glycan moieties and the GPI modifications act to 284 
route the protein to the apical membrane of epithelial cells in the TAL, this is when UMOD is finally GPI 285 
anchored and facing the tubular lumen, here it is said to form supramolecular structures to ensure its proposed 286 
physiological properties are performed (81). The protein is released for the lumen side of the membrane by 287 
specific but currently unidentified protease(s). Proteolytic cleavage was originally thought to occur after residue 288 
F548 (50), but later thought F587 (151). Proteolytic cleavage of the GPI anchor still remains to be determined, 289 
however, once cleaved form the apical membrane UMOD forms polymers in the urine and becomes the most 290 
abundant protein in mammalian urine.  291 
Physiological and pathological roles of UMOD 292 
Due to UMODs structure it has one peculiar feature; it has a tendency to aggregate with gel like properties in 293 
solution when NaCl concentrations are close to 100 mmol/l or CaCl (calcium chloride) is 1 mmol/l (15, 23) 294 
which may be responsible for the binding properties of the protein. This along with the GPI anchoring and 295 
multidomain structure on the luminal side of the apical membrane, in conjunction with rich and highly variable 296 
post translational protein modification, and a large presence of polymerised protein in the urine suggests that 297 
UMOD may play multiple roles with site specific physiological functions. However, over 60 years of research 298 
has not elucidated the biological role of UMOD. Sorting of the apical membrane proteins requires GPI anchors, 299 
N-glycosylation, and polymerisation, with the large turnover of UMOD and its half-life of 16 hours it is 300 
assumed that the biosynthesis plays either a direct or indirect role in the formation of the apical membrane 301 
targeted cargo vesicles and vesicle trafficking. GPI anchored proteins associate with lipid raft domains that play 302 
a role in organising the apical membrane and signalling transduction pathways (142). When the apical 303 
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membrane is highly ordered it allows for close packing of GPI anchored proteins on the surface of cell 304 
membranes, in the case of UMOD this may promote formation of the complex gel like structures providing a 305 
water barrier at the luminal membrane of the TAL cells. This physical barrier to water permeability may play a 306 
role in ion transport to maintain counter current gradients in the interstitium (80).  307 
As the TAL are nephron segments characterised by high electrolyte and water impermeability it was proposed 308 
that UMOD plays a role in salt transports and acts as a water barrier at this level, a process crucial for urine 309 
concentration. Bleyer et al reported low urine osmolality was consistent in subjects with UMOD mutations (19). 310 
A transgenic mouse model for Uromodulin associated kidney diseases (UAKD) confirmed urinary concentrating 311 
deficit (16). Water reabsorption by the tubule is regulated by transmembrane systems of aquaporin and ion 312 
channels (3), Bachmann and colleagues studied the renal effects of UMOD deficiency in UMOD knockout mice 313 
and reported the inability of these mice to concentrate urine possibly due to a decrease in cyclooxygenase-2 314 
(COX-2) expression (10). COX-2 inhibition prevents regulation of key renal water and sodium transport 315 
proteins including aquaporin 2 (AQP2), NHE3, and NKCC2 (126), confirming the role of UMOD in urine 316 
osmolality. More commonly in the clinic, UMOD is associated with renal cystic diseases. These are a major 317 
group of inherited renal conditions, representing the leading cause of end stage renal disease. Cystic kidney 318 
disease (CKD), in both the dominant and recessive variants, accounts for the clinical conditions. Hart et al and 319 
Rampoldi et al discovered autosomal dominant mutations in UMOD lead to medullary cystic kidney disease 320 
type 2 (MCKD2), familial juvenile hyperuricemic nephropathy (FJHN), and glomerular cystic kidney disease 321 
(GCKD) (66, 143). These conditions are characterised by urinary concentration deficits, urinary salt wasting, 322 
hyperuricemia, gout, medullary cysts, interstitial nephritis, glomerular cysts, hypertension, and end stage renal 323 
failure. MCKD2 is autosomal dominant disorder is mainly characterised by hypertension and end stage renal 324 
failure, in the fourth decade of life, with renal complications including tubular membrane disintegration, tubular 325 
atrophy, with cyst development at the corticomedullary border and interstitial cell infiltration associated with 326 
fibrosis. MCKD2 has clinical and morphological overlap with the autosomal dominant FJHN. GCKD is 327 
characterised by a cystic dilatation of Bowmen’s capsule and collapse of the glomerulus (191). All three 328 
disorders have significant clinical overlap and arise from UMOD mutations and are often referred to as UAKD 329 
and are said to cause the so called “uromodulin storage disease” (177, 183). 330 
To date there have been more than 58 UMOD mutations reported, that mainly localise to exon 3 and 4 of the 331 
UMOD gene, with the majority being missense mutations or small inframe deletions (95). Early genome wide 332 
linkage mapping in Italian, Czech, and Belgian families revealed loci for MCKD and FJHN on chromosome 16 333 
in the regions of 16p11.2 and 16p12 (32, 166) in close proximity to the UMOD gene. These conditions are 334 
associated with mutations that lead to amino acid changes at cysteine sites causing defective protein folding and 335 
immature UMOD being retained at the ER and not released at the apical membrane and remains intracellular 336 
(16, 143). Accumulation of misfolded UMOD in the ER causes ER stress and degradation by increased 337 
synthesis of chaperones and foldases that in turn activate the misfolded protein (90). This unfolded protein 338 
response may trigger apoptosis and autophagy or alternatively lead to cell activation via MAP kinases and NF-339 
kB leading to the eventual progressive renal failure seen in MCKD2, FJHN, and GCKD (96). It is known that 340 
the transcription factor hepatic nuclear factor 1-β (HNFIβ) positively regulates UMOD expression and binds to 341 
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the promoter elements of the gene. Inactivation of HNFIβ in vivo is associated with decreased UMOD 342 
transcription (100). Interestingly mutations of HNFIβ are associated with features of MCKD2, FJHN, and 343 
GCKD (160). This transcription factor is also known to regulate nephrocystins which prompted work by Zaucke 344 
et al in 2010 to investigate if UMOD is linked to cillary cystogenesis (191). They reported 7 novel UMOD 345 
mutations (missense or deletion mutations) between exon 4 - 5 and that UMOD is expressed in primary cilia of 346 
renal tubules and the number of UMOD positive tubules declines in UAKD. The mutations caused localisation 347 
of UMOD in the mitotic spindle poles co-localised with nephrocystin-1, suggesting a novel cause of cystic 348 
kidney disease pathologies of MCKD2, FJHN, and GCKD.  349 
In the absence of UMOD there is susceptibility to calcium oxalate stones due to the lack of gel like properties of 350 
the protein, thus altered salt concentration at the apical membrane is apparent (165). Mo et al showed that 351 
UMOD knockout mice spontaneously formed intra-renal crystals predominantly in the interstitial space and in 352 
the collecting duct of the deep medulla and papilla (118). They reported that the stones consisted primarily of 353 
calcium phosphate in the form of hydroxyapatite and strongly resemble the stones found in humans caused by 354 
idiopathic calcium oxalate stones. The inhibitory effect of UMOD in stone aggregation had been described in 355 
cases of calcium oxalate (13, 37). There is consensus that inhibition of stone formation in normal urine is caused 356 
mainly by urinary macromolecules rather than low molecular weight components, and this property has been 357 
associated with polyanionic structures (48). UMOD is said to be a polyanionic macromolecule due to the large 358 
extent of sialylation and presence of sulphate groups bound to the N-linked glycans thus playing a crucial role in 359 
regulating stone formation (172). Urinary tract infections (UTI’s) are mainly caused by E Coli, and critically 360 
depends on filamentous appendages on the bacterial surface called fimbriae (13). Colonisation is mediated by 361 
binding of lectin like adhesins present on E coli fimbriae to carbohydrate structures carried by glycoprotiens 362 
exposed at the cell surface. E coli fimbriae are classified according to their sugar specificity: type 1, type P, and 363 
type S, Pak et al illustrated that UMOD binds with type 1 E coli fimbriae in vitro, and Raffi et al described 364 
UMOD as a general host defence mechanism against urinary tract infections (132, 140) in vivo with a UMOD 365 
knockout mouse model, supporting the concept that urinary UMOD represents a protective mechanism against 366 
UTI’s. In terms of urinary excretion, in adults, there appears to be considerable variation in daytime excretion 367 
values, but does correlate with urinary volumes brought about with diuresis in those drinking in response to 368 
thirst (103). A positive correlation between urinary UMOD and dietary salt intake revealed that in subjects with 369 
high salt sensitivity i.e. exaggerated BP response to high salt intake, there is a greater excretion of UMOD in the 370 
urine compared low salt intake (168). UMOD excretion seems to increase gradually from birth to adulthood, 371 
where it remains stable until a decline after the sixth decade of life (129, 161), with urinary UMOD/creatinine 372 
ratio also remains stable from the age of 4 until the age of 70. Reduced urinary excretion of UMOD has also 373 
been correlated with GFR and corresponds to declining kidney function in virtually all chronic kidney diseases 374 
(138). In an attempt to elucidate why urinary UMOD excretion is altered in disease Ma et al studied potential 375 
mechanisms using human UMOD mutations in polarised Madin Darby canine kidney cells (MDCK). They 376 
report that cysteine mutations inside and out of the domain are able to specifically bind and trap UMOD 377 
preventing it from exiting the ER and translocating to the cell surface. However, they found specifically cysteine 378 
altering mutation in the cysteine rich domain had more sever deficits in ER exit and surface translocation, 379 
initiating increased apoptosis explaining partly in some diseases the marked reductions in urinary UMOD (104).  380 
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Uromodulin, blood pressure, and ion transport 381 
Genome-wide association studies recently linked more common genetic variants in the UMOD promoter with 382 
the risk of HTN (131). Our previous GWAS identified a locus upstream of the UMOD gene transcriptional start 383 
site, which was associated with altered BP (131). It was reported that the minor G allele of rs13333226 when 384 
adjusted for estimated glomerular filtration rate (eGFR) was associated with a 7 % lower risk of developing 385 
hypertension. This GWAS discovery followed by functional validation studies have now resulted in a re-386 
focussing of interest in UMOD and its role in BP regulation (56, 170). Results from our recent studies in 387 
UMOD-/- mice suggest a biological link between UMOD and ion transport in the TAL. In the absence of 388 
UMOD there is augmented sodium excretion in the UMOD-/- mice, thought to be a consequence of reduced 389 
expression of NKCC2. This modulated Na+ reabsorption by reduced NKCC2 leads to exaggerated natriuresis 390 
and lower arterial pressure in the UMOD-/- mice, consistent with findings in humans where salt wasting 391 
phenotypes and hypotension are characteristics of Bartter’s syndrome (139, 157, 174). In a complimentary set of 392 
experiments, Trudu et al demonstrated that uromodulin-transgenic mice over expressing UMOD manifested 393 
salt-sensitive hypertension, due to activation of the SPAK kinase and activating N-terminal phosphorylation of 394 
NKCC2 (170). Biochemical and histological analysis of UMOD has been used to assess changes in biosynthesis 395 
of proteins related to NaCl transport along the nephron in UMOD-/- mice. Bachmann et al revealed upregulation 396 
of major distal transporters (Na+/K+ -ATPase, NKCC2, NHE3, ROMK, and ENaC) and downregulation of 397 
juxtaglomerular apparatus components (10, 121). They reported that the augmented total NKCC2 expression 398 
was in fact as a result of increased intracellular expression of NKCC2, where it remained unphosphorylated and 399 
inactive in UMOD-/- mice (121). This group concluded that in the absence of UMOD the reduced NKCC2 400 
activity results in impaired NaCl reabsorption at the TAL, implying a permissive role of UMOD in the 401 
modulation of Na+ transport. ROMK resides in the apical membrane in the TAL and processes NaCl 402 
reabsorption via the recycling of K+ ions into the tubular lumen. It forms a functional unit with NKCC2, the rate 403 
limiting transporter. Disrupted ROMK function at the TAL limits NaCl reabsorption resulting in the salt wasting 404 
phenotypes observed in Bartter’s syndrome. Renigunta, et al identified UMOD as a ROMK interacting protein, 405 
regulating ROMK function by increasing its expression at the cell surface of the TAL apical membrane (145). 406 
Furthermore, this group observed a decrease in ROMK immunoreactivity in the plasma membrane enriched 407 
fractions of UMOD-/- mice kidney compared to UMOD+/+ counterparts. They demonstrated that UMOD 408 
ablation results in large accumulation of ROMK in the sub apical vesicles resulting in delayed or decreased 409 
surface expression leading to salt wasting. This accumulation of ROMK is a result of the fluid entering the TAL 410 
having high concentrations of Na+ and Cl- with low concentrations of K+. Therefore, efficient reabsorption of 411 
Na+ and Cl- would be prevented as the stochiometric flux of Na+ and K+ into the cell (via NKCC2) would 412 
quickly deplete K+ levels in the luminal fluid. This stimulation is normally avoided by the recycling of K+ 413 
entering the cell back into the lumen. Thus, the absence of K+ recycling results in markedly impaired NaCl 414 
reabsorption which may be occurring in the UMOD-/- mice. A physiological regulator of NKCC2 transport rate 415 
is the Cl- ion, in times of low luminal Cl- the activity of NKCC2 is attenuated (22, 57). Mutig et al have shown 416 
that activation of NKCC2 is facilitated by UMOD in a Cl- sensitive manner (121). These findings suggest 417 
inactivation of NKCC2 and ROMK explaining the phenotypes similar to Bartter we reported previously in these 418 
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mice (56). To date the differential expression analysis of the major Na+ handling transporters in the kidney of 419 
UMOD+/+ and UMOD-/- mice before and after salt loading has not been explored. 420 
PATHOPHYSIOLOGY OF THE TAL  421 
Given its role in renal physiology, it is not surprising that the TAL plays an important part in the 422 
pathophysiological role of disease. An extensive understanding of the TAL in renal ion transport systems will 423 
encourage precision medicine to provide stratified treatments for individuals. Single gene mutations present in 424 
Mendelian forms of HTN all increase Na+ reabsorption at the distal segments of the nephron, but not at the TAL 425 
(97, 182). Monogenic blood pressure disorders where TAL ion gene expression is altered result in hypotension, 426 
suggesting a role for variants in the TAL to lower rather than raise blood pressure, reducing the risk for HTN. 427 
Re-sequencing of three salt-handling genes (SLC12A3 (NCC), SLC12A1 (NKCC2), and KCNJ1 (ROMK)) in a 428 
cohort of over 5000 subjects of the Framingham Heart study showed the large influence rare variants have on 429 
BP (84). The authors documented 30 mutations in these 3 genes that were inferred to have functional 430 
consequences. Carriers of any of the rare variants in the three salt-handling genes (with minor allele frequency ≤ 431 
1 %) had mean reductions of 6.3 mmHg in SBP and 3.4 mm Hg in DBP, compared with the entire cohort. 432 
Mutation carriers had mean SBP values 6.6 mm Hg less than their non-carrier siblings. These are large effects 433 
when compared with those of common variants, for which the effect size is usually 1 mm Hg or less (84). 434 
Authors conclusively demonstrated that these variants were associated with lower BP (approximately 6-10 435 
mmHg) and were protective against increased risk for hypertension, emphasising the contribution of sodium 436 
handling in blood pressure regulation in the general populations. 437 
Studies so far suggest that variations in Na+ uptake by the TAL influence an individual’s chronic level of blood 438 
pressure. Loss-of-function mutations in TAL Na+-Cl− transport are associated with Bartter’s syndrome. Lifton 439 
and colleagues reported that Bartter’s syndrome results from mutations in NKCC2 or its regulators and is 440 
referred to as type 1 (156-158) . Cl− carried into the cell by NKCC2 exits through the Cl− channels CLCNKA 441 
and CLCNKB with facilitation by BSND (barttin gene). Mutations in CLCNKB and BSND result in, 442 
respectively, types 3 and 4 Bartter’s syndrome. Bartter’s syndrome type 3 is caused by mutations of the Cl- 443 
channel CLCNKB (156). NaCl entering the cell via NKCC2 at the apical membrane must exit the cell via the 444 
Na+ -K+ /ATPase at the basolateral membrane; however this mutation prevents normal Cl- exit due to inhibition 445 
of membrane localisation. Thus, the functional activity of NKCC2 and blood pressure control is determined by 446 
clearing excess Cl− from TAL cells. Additionally, these patients may have an increase in urinary Ca2+ excretion 447 
and approximately 20% are hypomagnesemic (59). Upon binding of the  Ca2+ sensing receptor (CASR) on the 448 
basolateral surface in TAL leads to inhibition of NKCC2 (74)  resulting in a more negatively charged lumen and 449 
less recycling of K+. These actions facilitate excretion of Ca2+, serving as a means for correcting and/or 450 
preventing a state of hypercalcemia. Loss of function mutations in ROMK also result in Bartter’s syndrome 451 
(Type 2). The mutations results in salt wasting as: fluid entering the TAL has increased concentrations of Na+ 452 
and Cl- with low K+ thus the stochiometric flux of Na+ and K+ via NKCC2 rapidly depletes K+ in the luminal 453 
fluid which prevents efficient reabsorption of Na+ and Cl- (157). This chain of events can be avoided by K+ 454 
entering back into the luminal fluid, implicating ROMK as the necessary channel for the recycling of K+ to 455 
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maintain Na+ and Cl- reabsorption, demonstrating the importance of synchronised actions of these channels in 456 
blood pressure regulation.  457 
Gitelman syndrome presents as a form of hypotension and renal sodium wasting caused by monogenic 458 
mutations. This condition is genetically homogeneous and is caused by loss of function mutations of the NCC 459 
transporter (Na-Cl co-transporter in the distal convoluted tubule (DCT)) (159). Patients usually present in 460 
adulthood with lower BP than the general population and display neuromuscular symptoms. These individuals 461 
have low serum Mg+ and low urinary Ca+ (17). The sodium wasting at the DCT activates the renin-angiotensin-462 
aldosterone system (RAAS), however in this condition there is augmented ENaC activity, protecting sodium 463 
homeostasis at the expense of increased H+ and K+ secretion. In order for Na+ reabsorption in TAL to reach a 464 
level sufficient to raise blood pressure it requires help from another nephron site. For example if 465 
Na+ reabsorption by NKCC2 was increased, the distal nephron should in response to the renin-angiotensin-466 
aldosterone system reduce Na+ downstream. Should these compensatory mechanisms not occur, a higher blood 467 
pressure could develop. When investigating the role of the TAL to increase blood pressure, the distal nephron or 468 
proximal tubule should be considered. Simultaneously, greater Na+ reabsorption elsewhere could require a more 469 
active TAL before manifesting in an increase in blood pressure. 470 
ROLE OF THE TAL IN SALT SENSITIVE HYPERTENSION 471 
A role for TAL in regulating blood pressure in humans is difficult to establish in the clinic setting due to 472 
limitations essential for medical assessments. If TAL function increased, the increments in Na+ reabsorption 473 
necessary to raise BP would be relatively small and only enough over time to exceed any adjustments either 474 
proximally or distally. For example, ENaC in the collecting duct reabsorbs only a small fraction of filtered Na+ 475 
(2%), thus Na+ reabsorption in TAL would need only to exceed this small fractional range to affect blood 476 
pressure. A more active TAL could explain greater proximal tubular reabsorption of Na+. This would result in 477 
reduced TGF followed by increased glomerular filtration thereby increasing delivery of Na+ to the proximal 478 
tubule that then increases absolute amounts of Na+ reabsorption (20). Indeed, Aviv et al extensively reviewed 479 
clinical studies demonstrating the TAL as a pivotal part of the nephron contributing to the heightened 480 
susceptibility salt sensitive hypertension (9). A plausible mechanism responsible was proposed as a consequence 481 
of increased NKCC2 activity leading to an expansion of extracellular volume, decreased urinary K+ excretion 482 
and increased Na+ reabsorption with greater water conservation. An increase in Na+ uptake by NKCC2 would 483 
enhance TGF (less Na+ reaching the macula densa) leading to glomerular hyperfiltration, delivering more Na+ to 484 
the proximal tubule resulting in an increase in the absolute amount of Na+ reabsorbed in the proximal tubule and 485 
downstream in TAL (85). In 2004, Sonalker et al illustrated that spontaneously hypertensive rats (SHR) had 4 486 
fold higher expression levels of total NKCC2 (163). This group later measured membrane bound and total 487 
NKCC2 in the outer medulla in these rats by subcellular fractionation and found no difference in the surface to 488 
intracellular ratio of NKCC2 (162). Yet, progression from normotension to hypertension (5 – 8 weeks of age) in 489 
SHR was accompanied by a two fold increase in the surface to intracellular ratio of NKCC2 (54). Additionally, 490 
in Dahl salt sensitive rats, NKCC2 dependent TAL transport, phosphorylation, and cell surface NKCC2 were 491 
enhanced upon salt loading with increased BP (65). Indicating that salt stimuli modulates NKCC2 trafficking 492 
beyond essential requirements altering Na+ uptake, ECF volume, and increasing arterial pressure. Zhou et al 493 
studied the effects of ROMKi B (a selective ROMK inhibitor) on systemic hemodynamics, renal function and 494 
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structure, and vascular function in Dahl salt-sensitive rats on a high salt diet (192). They reported a potential 495 
utility of ROMKi B as a novel antihypertensive agent, particularly for the treatment of the salt-sensitive 496 
hypertension patient population as this inhibitor promoted increased natriuresis without any adverse effects on 497 
electrolytes and acid–base balance, kidney function, and structure.  498 
Other TAL ion transporters may also contribute to salt sensitive hypertension; a high sodium intake increases 499 
the capacity of the TAL to absorb HCO3-. Good et al examined the role of the apical NHE3 and basolateral 500 
NHE1 Na(+)/H(+) exchangers in TAL tubules from salt sensitive rats drinking normal tap water or 0.28 M NaCl 501 
for 5-7 days (55). They reported that high sodium intake increased HCO3- absorption rate by 60% and this was 502 
mediated by an increase in apical NHE3 activity. Inhibiting basolateral NHE1 eliminated 60% of the HCO3- 503 
absorption. Demonstrating that during a high salt diet, these rats have increases in NHE3 activity dependent on 504 
NHE1. Studies in NHE3 KO mice report chronic volume depletion and hypotension (152). Furthermore, NHE3-505 
/- mice display blunted proximal fluid reabsorption without altered distal delivery of fluid (102). This 506 
compensation is largely attributable to decreased GFR due to activation of TGF suggesting normalisation of 507 
fluid delivery to the distal tubule is achieved through alterations in filtration rate and/or downstream transport 508 
processes. Reabsorption of filtered Na+ along the PCT in proportion to GFR suggests that rates of Na+ and fluid 509 
not being reabsorbed will change in proportion to the rate of filtration, denoting that despite glomerulotubular 510 
balance (GTB), delivery rate of Na+ to the tubular segments beyond the PCT will increase whenever GFR 511 
increases. Thus, Na+ homeostasis is regulated by TGF, a counter regulatory mechanism that senses an increase 512 
in NaCl delivery to the late nephron segments. These studies support a role of the TAL enabling the kidneys to 513 
regulate acid-base balance during changes in sodium and volume balance.  514 
Future direction 515 
A considerable body of evidence links salt sensitive hypertension with the role of the TAL. Further research in 516 
this area will enable development of a therapeutic application for targeted treatment. This is crucial because 517 
despite major advances in cardiovascular health, hypertension remains the risk factor contributing most to the 518 
overall burden of disease globally and there is a paucity of novel antihypertensive drugs in clinical trials or 519 
pharmaceutical development pipeline.   520 
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Figure captions 1085 
26 
 
Figure 1. Schematic of a nephron segment. 1086 
The nephron consists of a renal corpuscle, a proximal tubule, a loop of Henle, a distal tubule, and a collecting 1087 
duct system. The renal corpuscle consists of glomerular capillaries and Bowman’s capsule. The proximal tubule 1088 
initially forms several coils followed by a straight segment that descends into the medulla. The next segment is 1089 
the loop of Henle, which consists of a straight section of the proximal tubule, the descending thin limb (which 1090 
ends in a hair pin turn), the thin ascending limb, and the thick ascending limb. Near the end of the thick 1091 
ascending limb, the nephron passes between its afferent and efferent arterioles. The short segment of the thick 1092 
ascending limb is called the macula densa. The distal tubule begins a short distance beyond the macula densa 1093 
and extends to the point in the cortex where two or more nephrons join to form the cortical collecting duct. The 1094 
collecting ducts enter the medulla and become the outer medulla collecting ducts, and then the inner medullary 1095 
collecting ducts. In terms of ion transport the proximal tubule is responsible for 60 – 70 % of the filtered Na+, 1096 
whereas 15 – 25 % is absorbed by the loop of Henle. The distal tubule reabsorbs 5 – 10 % and the collecting 1097 
ducts only 1 -2 % (149). 1098 
Figure 2. Organisation of the Loop of Henle. 1099 
Structures are as follows: 1, thin descending limb of the loop of Henle; 2, thin ascending limb of the loop of 1100 
Henle; and 3, thick ascending limb of the loop of Henle. See main text for details relevant to the labelled 1101 
structures.  1102 
Figure 3. Schematic of a nephron segment indicating ion transporter positions.  1103 
PCT: Proximal convoluted tubule; TAL: Thick ascending limb of the loop of Henle; and DCT: Distal 1104 
convoluted tubule.  1105 
Figure 4.  Schematic of ion transport in the TAL by actions of (A) NHE3, (B) NKCC2.  1106 
ATP (adenosine triphosphate), CA (carbonic anhydrase), Ca+ (calcium), CO2 (carbon dioxide), Cl- (chloride), H+ 1107 
(hydrogen), H2O (water), H2CO3 (carbonic acid), ( HCO3- (bicarbonate), K+ (potassium), Mg+ (magnesium),  Na+ 1108 
(sodium), NKCC2 (Na+-K+-Cl- transporter), and ROMK (renal outer medullary potassium channel).  1109 
 1110 
 1111 
